Targets › ATPV1A1
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Jun 2027.
Open in Phaseline: the race on ATPV1A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital with Nanjing Medical University | VAB-7 Proton pump inhibitor (vonoprazan) combined with beta-lactam antibiotic (amoxicillin) and | ATPV1A1 | Phase 4 | Helicobacter Pylori | Jun 2027 |
Helicobacter Pylori (1)
small molecule (1)
The First Affiliated Hospital with Nanjing Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.